Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Sai-Hong Ignatius OuChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CAAbstract: Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Książka |
| Wydane: |
Dove Medical Press,
2011-11-01T00:00:00Z.
|
| Hasła przedmiotowe: | |
| Dostęp online: | Connect to this object online. |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sygnatura: |
A1234.567 |
|---|---|
| Egzemplarz 1 | Dostępne |